Jefferies Group Gives Buy (N/A) Rating to Array Biopharma Incorporated (ARRY)

By admin | 6 years ago

Array Biopharma Incorporated (NASDAQ: ARRY)‘s stock had its “buy (n/a)” rating restated by analysts at Jefferies Group (NYSE: JEF) in a research report issued to clients and investors on Tuesday.

Array Biopharma Incorporated opened at 3.20 on Tuesday. Array Biopharma Incorporated has a 1-year low of $1.58 and a 1-year high of $4.10. The company’s market cap is $285.2 million.

Array Biopharma Incorporated last released its earnings data on Monday, April 30th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. Analysts expect that Array Biopharma Incorporated will post $-0.19 EPS next quarter.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

About the author